LIMN (Liminatus Pharma) Inventories, Finished Goods: $0.00 Mil (As of Mar. 2026)


LIMN Liminatus Pharma Inc LIMN
13 GF Score
Price $0.11
! 1 Warning Sign
View Full Analysis

What is Liminatus Pharma Inventories, Finished Goods?

Liminatus Pharma LIMN -6.99% 13 Inventories, Finished Goods is $0.00 Mil as of Mar. 2026. GuruFocus rates LIMN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Liminatus Pharma Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Liminatus Pharma's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liminatus Pharma Inventories, Finished Goods Chart

Liminatus Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
0.00 0.00 0.00 0.00

Liminatus Pharma Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LIMN
13GF Score
Liminatus Pharma Inc LIMN
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Liminatus Pharma Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $0.00 Mil mean?
Liminatus Pharma (LIMN) has a Inventories, Finished Goods of $0.00 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Liminatus Pharma and its competitors.
Is Liminatus Pharma's Inventories, Finished Goods too high?
Liminatus Pharma's current Inventories, Finished Goods is $0.00 Mil. Overall, Liminatus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Liminatus Pharma's Inventories, Finished Goods compare to GNPX and PCSA?
Liminatus Pharma's Inventories, Finished Goods of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Liminatus Pharma and its competitors. Liminatus Pharma's current Inventories, Finished Goods is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current Inventories, Finished Goods of $0.00 Mil. The current Inventories, Finished Goods is $0.00 Mil. Liminatus Pharma's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current Inventories, Finished Goods is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Liminatus Pharma Business Description

Address 12611 Hiddencreek Way, Unit C, Cerritos, CA, USA, 90703
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
13GF Score

Get the complete analysis for LIMN

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price